Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Partners With Santaris On RNA Antagonists For Viral Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

$700 million deal gives GlaxoSmithKline options on up to four different viral disease programs; deal marks Santaris’ expansion into virology, chief exec McCullah tells “The Pink Sheet” DAILY.

You may also be interested in...



MicroRNA Momentum Builds, But Will Big Pharma Embrace It?

While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.

Wyeth And Santaris To Collaborate On RNA Antagonists

Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.

Wyeth And Santaris To Collaborate On RNA Antagonists

Danish biotech gets $7 million upfront, $10 million equity investment in Locked Nucleic Acid platform licensing agreement.

Related Content

Topics

UsernamePublicRestriction

Register

PS065541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel